E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Colorectal cancer liver metastases |
|
E.1.1.1 | Medical condition in easily understood language |
Bowel cancer spread to the liver |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10007095 |
E.1.2 | Term | Cancer of liver, secondary |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The trial aims to determine whether oral IPE therapy, started at least 2 weeks before surgery and continued for a minimum of 2 years, improves colorectal cancer recurrence in patients undergoing liver resection surgery for colorectal cancer liver metastases. |
|
E.2.2 | Secondary objectives of the trial |
To determine whether IPE treatment improves survival.
To confirm the safety and tolerability of IPE before and after surgery, including during chemotherapy.
To determine whether IPE treatment improves quality of life after colorectal cancer liver metastasis surgery, as reported by participants.
To determine the cost effectiveness of IPE treatment.
To determine whether IPE treatment has an effect on the diagnosis of new cancers.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Aged ≥18 years • Able to provide written informed consent • Histological diagnosis of colorectal cancer with evidence of liver metastases • Planned liver resection surgery for colorectal cancer liver metastasis with curative intent, including repeat ‘re-do’ colorectal cancer liver metastasis liver surgery (a second independent resection for a separate colorectal cancer liver recurrence) • Intention to receive ≥2 weeks treatment with IMP prior to colorectal cancer liver metastasis surgery
|
|
E.4 | Principal exclusion criteria |
• Incurable extra-hepatic metastases • Current (in the last 2 months) or planned regular (>3 doses per week) use of O3FA-containing supplements, including fish oil and cod-liver oil supplements • Fish/seafood allergy • <2 weeks before planned CRCLM surgery • Inability to comply with trial treatment and follow-up schedule • Known bleeding tendency/condition (e.g. von Willebrand disease) • A previous malignancy within the last 5 years other than: - colorectal cancer - non-melanoma skin cancer where treatment consisted of resection only or radiotherapy - ductal carcinoma in situ (DCIS) where treatment consisted of resection only - cervical carcinoma in situ where treatment consisted of resection only - superficial bladder carcinoma where treatment consisted of resection only • A previous malignancy where the patient has been disease-free for ≤5 years • Pregnant or breastfeeding women or women of childbearing potential not willing to use effective contraceptive measures. Women of childbearing potential are defined as fertile, following menarche and until becoming post-menopausal unless permanently sterile. • Men defined as fertile (post-pubescent and not permanently sterile by bilateral orchidectomy) and not willing to use effective contraceptive measures if appropriate.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is progression free survival (PFS) during a minimum of 2 years follow-up. PFS is defined as the time from randomisation to death (from any cause), first documented evidence of disease progression, new recurrence or clinical deterioration unequivocally due to disease progression.
The date of clinical progression is defined as the date of the CT scan or relevant assessment at which disease progression or new recurrence is identified. This can be clinical progression or, for RECIST evaluable disease, radiological progression by RECIST principles. For participants who have clear clinical symptoms of disease progression without confirmatory imaging, the date of progression is defined as the date of the clinical assessment.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint is evaluated at every visit from visit 3 onwards. |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are: • Overall Survival (OS), defined as the time from randomisation to death, from any cause (key secondary endpoint) • Safety and tolerability of IPE before and after CRCLM surgery, including during chemotherapy • Patient reported quality of life, measured using the EQ-5D, EORTC QLQ-C30 and QLQ-LMC21 questionnaires • Cost-effectiveness of IPE • New primary cancers (excluding DCIS, cervical carcinoma in situ, superficial bladder carcinoma where treatment consisted of resection only and non-melanoma skin cancer where treatment consisted of resection or radiotherapy only)
The exploratory endpoints are: • Red blood cell membrane EPA content, measured at baseline, surgery and 6 months after surgery (only patients from Leeds and Sheffield) • Change in lean body mass measured by CT scanning during follow up as assessed by the L3 skeletal muscle index score
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Overall survival is evaluated at every visit from visit 2 onwards.
Safety and tolerability of IPE is evaluated at every visit from visit 2 onwards and at fornightly telephone calls with the research nurse between visit 1 and visit 2 and at the telephone call with the research nurse at 60 days after visit 10/exit visit.
Patient reported quality of life is collected at visit 1, visit 3 and all visits thereafter.
Health economic data is collected at all visits and information on hospital resource activity will also be collected at fornightly telephone calls with the research nurse between visit 1 and visit 2.
Evaluation for new primary cancers will take place at every visit from visit 3 onwards.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is defined as the date of the collection of the last participant’s last data item. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |